IRMDIRADIMED CORPORATION
Is the price fair?
A demanding price: priced for +17% a year vs +13% a year delivered and rich vs its sector.
Priced for ~17% a year FCF growth. The price demands more than its three-year revenue growth of 13% a year, priced for acceleration.
In its normal range: P/E 48.9 vs a 35.9 median over 39 quarters (+36% vs median).
Sector median 22.6× across 130 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What IRMD's price assumes
IRADIMED CORPORATION trades at 48.9× earnings against 26.2× for the median Medical Devices name, more expensive than its own group.
Trailing P/E · Medical Devices median 26.2 · 1.87× the median: the market pays up for this one
- Price / sales
- 14.3
Price / sales · today's price, fiscal year to Dec 31, 2025
- Free cash flow yield
- 2.1%
Free cash flow yield · Medical Devices median 4.5%
- Growth the price implies
- +17%
Growth the price implies · The price pays for +17% free cash flow growth a year for a decade; the business has delivered +46% a year over the last three.
Details›
- Price / booktoday's price, fiscal year to Dec 31, 2025
- 12.7
- EV / EBITtoday's price, fiscal year to Dec 31, 2025
- 43.9
- EV / salestoday's price, fiscal year to Dec 31, 2025
- 13.7
- Healthcare median P/E509 names
- 26.2
- Medical Devices median P/E64 names
- 26.2
- Free cash flow, trailing twelve months
- $25M
- Market capitalisation
- $1.20B
- 3-year revenue growth
- +13%
- 3-year free cash flow growth
- +46%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $52.19 |
| Its own P/E history, median | $64.33 |
| Its own P/E history, upper quartile | $96.51 |
| 52-week range | $67.77 – $104.87 |
| Today | $87.53 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.